ERBB2 and breast cancer: The proteomic analysis of SKBR3/HER2+ breast cancer cells treated with the EGFR/ERBB2 receptor Tyr kinase inhibitor Lapatinib and pan-AKT Ser/Thr kinase inhibitor Ipatasertib revealed that the drugs exerted a wide-ranging impact on signaling and biological processes that support cancer progression.